gdc-0941 and Neoplasms

gdc-0941 has been researched along with Neoplasms* in 5 studies

Reviews

2 review(s) available for gdc-0941 and Neoplasms

ArticleYear
Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.
    European journal of medicinal chemistry, 2019, Dec-01, Volume: 183

    Phosphatidylinositol-3 kinase (PI3K) pathway is one of the most frequently activated pathogenic signaling cascades in human malignancies. PI3K is genetically mutated or overexpressed in a wide variety of cancers including ovarian, breast, prostate, gastric, colorectal, glioblastoma, endometrial and brain cancers. Studies are still ongoing to find more efficient and selective PI3K inhibitors or dual PI3K inhibitors to overcome the resistance to the current inhibitors. This review will focus on the three main classes of PI3K inhibitors with efficacious antitumor activity which are: isoform-selective PI3K inhibitors, dual pan-Class I PI3K/m-TOR inhibitors, and pan-Class I PI3K inhibitors without significant m-TOR activity. Isoform-selective PI3K inhibitors are classified into four classes IA, IB, II, and III. Moreover, SAR among each class, together with the biological activity will be discussed. In addition, the new scopes for the design of novel candidates to overcome emerging resistance will be highlighted as well.

    Topics: Antineoplastic Agents; Drug Design; Drug Resistance, Multiple; Humans; Molecular Targeted Therapy; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors

2019
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
    Bioorganic & medicinal chemistry, 2012, Mar-15, Volume: 20, Issue:6

    Over the past few decades, panels of human cancer cell lines have made a significant contribution to the discovery and development of anticancer drugs. The National Cancer Institute 60 (NCI60), which consists of 60 cell lines from various human cancer types, remains the most powerful human cancer cell line panel for high throughput screening of anticancer drugs. The development of JFCR39, comprising a panel of 39 human cancer cell lines coupled with a drug-activity database, was based on NCI60. Like NCI60, JFCR39 not only provides disease-oriented information but can also predict the action mechanism or molecular target of a given antitumor agent by utilizing the COMPARE algorithm. The molecular targets of ZSTK474 as well as several other antitumor agents have been identified by using JFCR39 and some of these compounds have since entered clinical trials. In this review, we will describe human cancer cell line panels particularly JFCR39 and its application in the discovery and/or development of anticancer drug candidates.

    Topics: Algorithms; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Discovery; Drug Screening Assays, Antitumor; Humans; National Cancer Institute (U.S.); Neoplasms; Triazines; United States

2012

Other Studies

3 other study(ies) available for gdc-0941 and Neoplasms

ArticleYear
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
    Journal of medicinal chemistry, 2017, 09-14, Volume: 60, Issue:17

    Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR). Here we describe the preclinical characterization of compound 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concentrations. No off-target interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand assays. Moreover, 1 did not bind tubulin, which was observed for the structurally related 4 (BKM120, buparlisib). Compound 1 is orally available, crosses the blood-brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs. Compound 1 demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model. This, together with the compound's safety profile, identifies 1 as a clinical candidate with a broad application range in oncology, including treatment of brain tumors or CNS metastasis. Compound 1 is currently in phase II clinical trials for advanced solid tumors and refractory lymphoma.

    Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Brain; Cell Proliferation; Dogs; Humans; Mice; Models, Molecular; Morpholines; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Rats; Rats, Nude; Signal Transduction; TOR Serine-Threonine Kinases

2017
Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
    Bioorganic & medicinal chemistry letters, 2012, Mar-01, Volume: 22, Issue:5

    Phosphoinositide-3-kinase (PI3K) is an important target for cancer therapeutics due to the deregulation of its signaling pathway in a wide variety of human cancers. We describe herein a novel series of imidazo[1,2-a]pyrazines as PI3K inhibitors.

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Imidazoles; Mice; Microsomes, Liver; Models, Molecular; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction

2012
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
    Journal of medicinal chemistry, 2008, Sep-25, Volume: 51, Issue:18

    Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/ Akt signaling pathway in a wide variety of tumors. A series of thieno[3,2-d]pyrimidine derivatives were prepared and evaluated as inhibitors of PI3 kinase p110alpha. The synthesis, biological activity, and further profiling of these compounds are described. This work resulted in the discovery of 17, GDC-0941, which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clinical trials for the treatment of cancer.

    Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indazoles; Magnetic Resonance Spectroscopy; Molecular Structure; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Sulfonamides

2008